Skip to main content
SpringerLink
Log in

Neuromyelitis-optica-Spektrum-Erkrankung

Neuromyelitis optica spectrum disorders

  • SOP/Algorithmus
  • Published:
DGNeurologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 9:14. https://doi.org/10.1186/1742-2094-9-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mori M, Kuwabara S, Paul F (2018) Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 89:555–556. https://doi.org/10.1136/jnnp-2017-317566

    Article  PubMed  Google Scholar 

  3. Borisow N, Mori M, Kuwabara S et al (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 9:888. https://doi.org/10.3389/fneur.2018.00888

    Article  PubMed  PubMed Central  Google Scholar 

  4. Borisow N, Kleiter I, Gahlen A et al (2017) Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler 23:1092–1103. https://doi.org/10.1177/1352458516671203

    Article  PubMed  Google Scholar 

  5. Gold SM, Willing A, Leypoldt F et al (2019) Sex differences in autoimmune disorders of the central nervous system. Semin Immunopathol 41:177–188. https://doi.org/10.1007/s00281-018-0723-8

    Article  PubMed  Google Scholar 

  6. Waters P, Reindl M, Saiz A et al (2016) Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 87:1005–1015. https://doi.org/10.1136/jnnp-2015-312601

    Article  PubMed  PubMed Central  Google Scholar 

  7. Narayan R, Simpson A, Fritsche K et al (2018) MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66–72. https://doi.org/10.1016/j.msard.2018.07.025

    Article  PubMed  Google Scholar 

  8. Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134. https://doi.org/10.1186/s12974-018-1144-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ogawa R, Nakashima I, Takahashi T, Kaneko K (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4:e322. https://doi.org/10.1212/NXI.0000000000000322

    Article  PubMed  PubMed Central  Google Scholar 

  10. Asseyer S, Schmidt F, Chien C et al (2018) Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. https://doi.org/10.1177/2055217318796684

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chavarro VS, Mealy MA, Simpson A et al (2016) Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000000286

    Article  PubMed  PubMed Central  Google Scholar 

  12. Penner I‑K, Paul F (2017) Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol 13:662–675. https://doi.org/10.1038/nrneurol.2017.117

    Article  PubMed  Google Scholar 

  13. Jarius S, Jacobi C, de Seze J et al (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067–1073. https://doi.org/10.1177/1352458511403958

    Article  CAS  PubMed  Google Scholar 

  14. Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci 306:82–90. https://doi.org/10.1016/j.jns.2011.03.038

    Article  CAS  PubMed  Google Scholar 

  15. Jarius S, Eichhorn P, Franciotta D et al (2017) The MRZ reaction as a highly specific marker of multiple sclerosis: Re-evaluation and structured review of the literature. J Neurol 264:453–466. https://doi.org/10.1007/s00415-016-8360-4

    Article  CAS  PubMed  Google Scholar 

  16. Flanagan EP, Weinshenker BG, Krecke KN et al (2015) Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 72:81–87. https://doi.org/10.1001/jamaneurol.2014.2137

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. https://doi.org/10.1212/WNL.0000000000001729

    Article  PubMed  PubMed Central  Google Scholar 

  18. Geraldes R, Ciccarelli O, Barkhof F et al (2018) The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol 14:199–213. https://doi.org/10.1038/nrneurol.2018.14

    Article  PubMed  Google Scholar 

  19. Kim HJ, Paul F, Lana-Peixoto MA et al (2015) MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 84:1165–1173. https://doi.org/10.1212/WNL.0000000000001367

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ramanathan S, Prelog K, Barnes EH et al (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22:470–482. https://doi.org/10.1177/1352458515593406

    Article  CAS  PubMed  Google Scholar 

  21. Schmidt F, Zimmermann H, Mikolajczak J et al (2017) Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 11:45–50. https://doi.org/10.1016/j.msard.2016.11.008

    Article  PubMed  Google Scholar 

  22. Oertel FC, Zimmermann H, Paul F, Brandt AU (2018) Optical coherence tomography in neuromyelitis optica spectrum disorders: Potential advantages for individualized monitoring of progression and therapy. EPMA J 9:21–33. https://doi.org/10.1007/s13167-017-0123-5

    Article  PubMed  Google Scholar 

  23. Oertel FC, Havla J, Roca-Fernández A et al (2018) Retinal ganglion cell loss in neuromyelitis optica: A longitudinal study. J Neurol Neurosurg Psychiatry 89:1259–1265. https://doi.org/10.1136/jnnp-2018-318382

    Article  PubMed  Google Scholar 

  24. Oertel FC, Kuchling J, Zimmermann H et al (2017) Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 4:e334. https://doi.org/10.1212/NXI.0000000000000334

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fang B, McKeon A, Hinson SR et al (2016) Autoimmune glial fibrillary acidic protein astrocytopathy: A novel meningoencephalomyelitis. JAMA Neurol 73:1297–1307. https://doi.org/10.1001/jamaneurol.2016.2549

    Article  PubMed  Google Scholar 

  26. Kleiter I, Gahlen A, Borisow N et al (2018) Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5(6):e504. https://doi.org/10.1212/NXI.0000000000000504

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346–351. https://doi.org/10.1136/jnnp-2017-316286

    Article  PubMed  Google Scholar 

  28. Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16. https://doi.org/10.1007/s00415-013-7169-7

    Article  CAS  PubMed  Google Scholar 

  29. Paul F, Murphy O, Pardo S, Levy M (2018) Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 27:265–271. https://doi.org/10.1080/13543784.2018.1443077

    Article  CAS  PubMed  Google Scholar 

  30. Cree BAC, Bennett JL, Sheehan M et al (2016) Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. Mult Scler 22:862–872. https://doi.org/10.1177/1352458515620934

    Article  CAS  PubMed  Google Scholar 

  31. Marcinnò A, Marnetto F, Valentino P et al (2018) Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 5:e498. https://doi.org/10.1212/NXI.0000000000000498

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland

    N. Siebert & F. Paul

  2. Experimental and Clinical Research Center, Max-Delbrück-Centrum für Molekulare Medizin und Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    F. Paul

Authors
  1. N. Siebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Siebert.

Ethics declarations

Interessenkonflikt

N. Siebert erhielt Reisestipendien von Sanofi-Aventis/Genzyme. F. Paul ist im wissenschaftlichen Beirat von Novartis tätig; erhielt Vortragshonorare und Reiseförderung von Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune und Shire; ist akademischer Herausgeber für PLoS One, ist Mitherausgeber für Neurology® Neuroimmunology & Neuroinflammation; war beratend tätig für Sanofi-Genzyme, Biogen Idec, MedImmune, Shire und Alexion; erhielt Forschungsunterstützung von Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, Deutsche Forschungsgemeinschaft, Werth-Stiftung der Stadt Köln, Bundesministerium für Bildung und Forschung, Arthur Arnstein Stiftung Berlin, EU FP7 Rahmenprogramm, Arthur Arnstein Stiftung Berlin, Guthy-Jackson Charitable Foundation und National Multiple Sclerosis Society of the USA.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

G. Fink, Köln

J.P. Sieb, Stralsund

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siebert, N., Paul, F. Neuromyelitis-optica-Spektrum-Erkrankung. DGNeurologie 2, 280–284 (2019). https://doi.org/10.1007/s42451-019-0081-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42451-019-0081-3

Search

Navigation